Clinical TrialJul 13, 2026, 07:01 AM
Kamada's CYTOGAM Study Shows Improved Outcomes in Lung Transplants
AI Summary
Kamada Ltd. highlighted positive results from an Investigator-Initiated Study on CYTOGAM® (Cytomegalovirus Immune Globulin) for solid organ transplantation, presented at the 2026 ISHLT annual meeting. The study found that CMVIG prophylaxis improved clinical outcomes and reduced activated innate immune cells in high-risk lung transplant recipients. These findings suggest CYTOGAM® may interrupt injurious innate immune responses and could shift the understanding of CMV management in lung transplants. Kamada's CEO anticipates these data will support increased product utilization.
Key Highlights
- Kamada highlighted positive results for CYTOGAM® at the 2026 ISHLT annual meeting.
- Study found CMVIG prophylaxis improved clinical outcomes in high-risk lung transplant recipients.
- Patients receiving CMVIG prophylaxis showed less activated innate immune cells.
- Non-clinical model indicated CMVIG blunted lung injury and improved mortality.
- Results are consistent with a prior Investigator-Initiated Study from 2023.
- Kamada CEO expects data to support increased CYTOGAM® product utilization.
Price Impact
More from KMDA